Epperly Melissa B sold $641k of ROIV
director at Roivant Sciences Ltd.. 17,750 shares at an average of $36.10, traded Oct 1, 2026, filed Oct 5, 2026.
Score components
- +15RoleDirector
- +20Trade size$641k at market
- +20Share of holdings soldSold 54% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001807359-26-000018, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 1, 2026 | MOption exercise Common Shares10b5-1 | +17,750 | $4.46 | $79k | 32,704 | 9 d ago |
| Oct 1, 2026 | SOpen-market sale Common Shares10b5-1 | -16,850 | $36.08 | $608k | 15,854 | 9 d ago |
| Oct 1, 2026 | SOpen-market sale Common Shares10b5-1 | -900 | $36.57 | $33k | 14,954 | 9 d ago |
| Oct 1, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -17,750 | $0.00 | $0 | 151,416 | 9 d ago |
Related signals
Other insiders at Roivant Sciences Ltd. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 28Weak | Roivant Sciences Ltd. | Eric Venker President & Immunovant CEO | $7.3M 200,000 shares | -11% | |
| 25Weak | Roivant Sciences Ltd. | Epperly Melissa B director | $196k 4,938 shares | -33% | |
| 20Weak | Roivant Sciences Ltd. | Meghan Fitzgerald director | $203k 5,112 shares | -12% | |
| 27Weak | Roivant Sciences Ltd. | Meghan Fitzgerald director | $798k 20,000 shares | -32% | |
| 35Weak | Roivant Sciences Ltd. | Eric Venker President & Immunovant CEO | $7.2M 200,000 shares | -11% | |
| 38Weak | Roivant Sciences Ltd. | Mayukh Sukhatme President & CIO | $12M 335,174 shares | -2% | |
| 38Weak | Roivant Sciences Ltd. | Mayukh Sukhatme President & CIO | $24M 664,826 shares | -4% | |
| 20Weak | Roivant Sciences Ltd. | Eric Venker President & Immunovant CEO | $7.0M 200,000 shares | -11% | |
| 15Weak | Roivant Sciences Ltd. | Meghan Fitzgerald director | $349k 10,000 shares | -19% | |
| 35Weak | Roivant Sciences Ltd. | Epperly Melissa B director | $610k 17,750 shares | -52% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.